Compare Stocks: ALEC, ABUS, DSGN, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.67 +2.0%	$4.56	$3.31 ▼ $5.38	$904.72M	0.64	1.30 million shs	1.44 million shs
ALEC Alector	$1.96 -3.9%	$1.70	$1.09 ▼ $3.40	$218.85M	0.6	1.06 million shs	596,373 shs
DSGN Design Therapeutics	$14.83 +3.1%	$13.12	$4.68 ▼ $17.25	$900.55M	1.63	440,906 shs	259,839 shs
KURA Kura Oncology	$10.86 +7.6%	$10.22	$6.95 ▼ $12.49	$895.73M	0.38	1.29 million shs	1.89 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.97%	+0.86%	+2.41%	+10.14%	+38.58%
ALEC Alector	-3.92%	+10.11%	+30.67%	-9.26%	-10.05%
DSGN Design Therapeutics	+3.06%	+6.00%	+9.69%	+3.20%	+173.62%
KURA Kura Oncology	+7.63%	+13.48%	-4.15%	+17.79%	+67.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.67 +2.0%	$4.56	$3.31 ▼ $5.38	$904.72M	0.64	1.30 million shs	1.44 million shs
ALEC Alector	$1.96 -3.9%	$1.70	$1.09 ▼ $3.40	$218.85M	0.6	1.06 million shs	596,373 shs
DSGN Design Therapeutics	$14.83 +3.1%	$13.12	$4.68 ▼ $17.25	$900.55M	1.63	440,906 shs	259,839 shs
KURA Kura Oncology	$10.86 +7.6%	$10.22	$6.95 ▼ $12.49	$895.73M	0.38	1.29 million shs	1.89 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.97%	+0.86%	+2.41%	+10.14%	+38.58%
ALEC Alector	-3.92%	+10.11%	+30.67%	-9.26%	-10.05%
DSGN Design Therapeutics	+3.06%	+6.00%	+9.69%	+3.20%	+173.62%
KURA Kura Oncology	+7.63%	+13.48%	-4.15%	+17.79%	+67.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	7.07% Upside
ALEC Alector	2.13	Hold	$3.63	84.95% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	11.26% Upside
KURA Kura Oncology	2.69	Moderate Buy	$25.62	135.87% Upside

Current Analyst Ratings Breakdown

Latest ALEC, ABUS, DSGN, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/28/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/17/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	KURA Kura Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/15/2026	KURA Kura Oncology	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
6/15/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
6/4/2026	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/4/2026	KURA Kura Oncology	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$181.72M	5.08	N/A	N/A	$1.31 per share	3.56
ALEC Alector	$13.86M	15.79	N/A	N/A	($0.09) per share	-21.78
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
KURA Kura Oncology	$77.23M	12.48	N/A	N/A	$0.55 per share	19.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	5.91	N/A	N/A	84.22%	90.98%	82.34%	N/A
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	N/A
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	N/A
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)

Latest ALEC, ABUS, DSGN, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ALEC Alector	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	54.26
ALEC Alector	0.80	5.26	5.26
DSGN Design Therapeutics	N/A	18.86	18.86
KURA Kura Oncology	0.12	4.73	6.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ALEC Alector	85.83%
DSGN Design Therapeutics	56.64%
KURA Kura Oncology	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
ALEC Alector	8.30%
DSGN Design Therapeutics	17.10%
KURA Kura Oncology	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	197.54 million	158.23 million	Optionable
ALEC Alector	270	111.66 million	102.39 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
KURA Kura Oncology	130	88.77 million	82.03 million	Optionable

ALEC, ABUS, DSGN, and KURA Headlines

Recent News About These Companies

Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says

August 15 at 4:07 AM | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up on Better-Than-Expected Earnings

August 15 at 1:21 AM | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

August 14 at 2:39 PM | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Kura Oncology (KURA) and Inovio Pharmaceuticals (INO)

August 14 at 12:37 PM | theglobeandmail.com

Kura Oncology (NASDAQ:KURA): What Does the Latest Update Mean for Clinical Evidence?

August 14 at 12:37 PM | kalkinemedia.comK

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

August 14 at 8:56 AM | marketbeat.com

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

August 13 at 10:19 AM | marketbeat.com

Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush

August 13 at 9:23 AM | marketbeat.com

Kura Oncology, Inc.: Kura Oncology Reports Second Quarter 2026 Financial Results

August 13 at 8:13 AM | finanznachrichten.de

Kura outlines $90M-$110M 2027 collaboration revenue while targeting 2028 KOMET-017 topline results

August 13 at 8:13 AM | seekingalpha.com

Kura Oncology, Inc. Q2 2026 Earnings Call Summary

August 13 at 8:13 AM | finance.yahoo.com

Kura Oncology: Q2 Earnings Snapshot

August 12 at 12:38 AM | sfgate.com

Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript

August 12 at 10:00 PM | seekingalpha.com

Kura Oncology Q2 Earnings Call Highlights

August 12 at 8:02 PM | marketbeat.com

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 6:41 PM | zacks.com

Kura Oncology (NASDAQ:KURA) Issues Earnings Results

August 12 at 5:40 PM | marketbeat.com

Kura Oncology Reports Second Quarter 2026 Financial Results

August 12 at 4:02 PM | globenewswire.com

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

August 10, 2026 | markets.businessinsider.com

Kura Oncology Announces Blood Publication Detailing Discovery, Preclinical Characterization and Resistance Profile of Ziftomenib

August 10, 2026 | quiverquant.comQ

Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity

August 10, 2026 | globenewswire.com

Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, ABUS, DSGN, and KURA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.67 +0.09 (+1.97%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.67 +0.00 (+0.09%)

As of 08/14/2026 07:58 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Alector NASDAQ:ALEC

$1.96 -0.08 (-3.92%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.83 -0.13 (-6.84%)

As of 08/14/2026 07:55 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Design Therapeutics NASDAQ:DSGN

$14.83 +0.44 (+3.06%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.81 -0.02 (-0.13%)

As of 08/14/2026 07:34 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Kura Oncology NASDAQ:KURA

$10.86 +0.77 (+7.63%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$10.91 +0.05 (+0.45%)

As of 08/14/2026 07:34 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, ABUS, DSGN, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, ABUS, DSGN, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, ABUS, DSGN, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, ABUS, DSGN, and KURA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Alector NASDAQ:ALEC

Design Therapeutics NASDAQ:DSGN

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, ABUS, DSGN, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, ABUS, DSGN, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, ABUS, DSGN, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, ABUS, DSGN, and KURA Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Alector NASDAQ:ALEC

Design Therapeutics NASDAQ:DSGN

Kura Oncology NASDAQ:KURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools